
## Simion I Chiosea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5156096/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. Cancer Discovery, 2013, 3, 761-769.	9.4	505
2	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 nextâ€generation sequencing assay. Cancer, 2014, 120, 3627-3634.	4.1	445
3	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	21.4	394
4	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid, 2015, 25, 1217-1223.	4.5	344
5	Up-Regulation of Dicer, a Component of the MicroRNA Machinery, in Prostate Adenocarcinoma. American Journal of Pathology, 2006, 169, 1812-1820.	3.8	327
6	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. JAMA Oncology, 2019, 5, 204.	7.1	317
7	First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. Cancer Discovery, 2012, 2, 694-705.	9.4	260
8	Overexpression of Dicer in Precursor Lesions of Lung Adenocarcinoma. Cancer Research, 2007, 67, 2345-2350.	0.9	230
9	Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nature Communications, 2017, 8, 14121.	12.8	227
10	Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology, 2012, 61, 387-394.	2.9	222
11	DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Modern Pathology, 2012, 25, 919-929.	5.5	203
12	SMARCB1 (INI-1)-deficient Sinonasal Carcinoma. American Journal of Surgical Pathology, 2017, 41, 458-471.	3.7	198
13	Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Modern Pathology, 2008, 21, 742-747.	5.5	188
14	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics, 2014, 46, 1166-1169.	21.4	188
15	The Profile of Acinic Cell Carcinoma After Recognition of Mammary Analog Secretory Carcinoma. American Journal of Surgical Pathology, 2012, 36, 343-350.	3.7	183
16	Extracapsular spread in head and neck carcinoma: Impact of site and human papillomavirus status. Cancer, 2013, 119, 3302-3308.	4.1	159
17	Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. Journal of Clinical Investigation, 2015, 126, 169-180.	8.2	156
18	Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer, 2008, 113, 2082-2089.	4.1	128

#	Article	IF	CITATIONS
19	Novel <i>PRKD</i> gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes and Cancer, 2014, 53, 845-856.	2.8	128
20	Salivary Duct Carcinoma. American Journal of Surgical Pathology, 2015, 39, 705-713.	3.7	126
21	MicroRNA Expression Profiles in Thyroid Tumors. Endocrine Pathology, 2009, 20, 85-91.	9.0	110
22	The cytological features of mammary analogue secretory carcinoma. Cancer Cytopathology, 2013, 121, 234-241.	2.4	105
23	Molecular Characterization of Apocrine Salivary Duct Carcinoma. American Journal of Surgical Pathology, 2015, 39, 744-752.	3.7	102
24	Early Oral Tongue Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 1104.	2.2	102
25	Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene, 2010, 29, 5135-5145.	5.9	94
26	Carcinoma Ex-Schneiderian Papilloma (Malignant Transformation): A Clinicopathologic and Immunophenotypic Study of 20 Cases Combined with a Comprehensive Review of the Literature. Head and Neck Pathology, 2014, 8, 269-286.	2.6	94
27	Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. American Journal of Surgical Pathology, 2018, 42, 442-452.	3.7	91
28	Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 117-118.	2.8	84
29	Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the <i>BRAF<sup>K601E</sup></i> Mutation. Thyroid, 2016, 26, 242-247.	4.5	83
30	Frequent <i>IDH2</i> R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. Journal of Pathology, 2017, 242, 400-408.	4.5	83
31	Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules. Endocrine-Related Cancer, 2016, 23, 295-301.	3.1	81
32	Phosphaturic Mesenchymal Tumors. American Journal of Surgical Pathology, 2017, 41, 1371-1380.	3.7	77
33	A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma. Endocrine Pathology, 2009, 20, 122-126.	9.0	74
34	Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, <i>PLAG1</i> or <i>HMGA2</i> rearrangements, and common genetic alterations. Cancer, 2016, 122, 3136-3144.	4.1	73
35	HRAS Mutations in Epithelial–Myoepithelial Carcinoma. Head and Neck Pathology, 2014, 8, 146-150.	2.6	72
36	Human papillomavirus and Epstein–Barr virus in nasopharyngeal carcinoma in a lowâ€incidence population. Head and Neck, 2014, 36, 511-516.	2.0	71

#	Article	IF	CITATIONS
37	Epithelial-Myoepithelial Carcinoma. American Journal of Surgical Pathology, 2018, 42, 18-27.	3.7	71
38	GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid, 2019, 29, 161-173.	4.5	69
39	Large Cell Neuroendocrine Carcinoma of the Larynx: Definition of an Entity. Head and Neck Pathology, 2010, 4, 198-207.	2.6	68
40	Mucoepidermoid carcinoma: a five-decade journey. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 133-140.	2.8	68
41	Selective expression of gastric mucin MUC6 in colonic sessile serrated adenoma but not in hyperplastic polyp aids in morphological diagnosis of serrated polyps. Modern Pathology, 2008, 21, 660-669.	5.5	67
42	PIK3CA Mutations and PTEN Loss in Salivary Duct Carcinomas. American Journal of Surgical Pathology, 2013, 37, 1201-1207.	3.7	66
43	KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Modern Pathology, 2013, 26, 1346-1354.	5.5	65
44	Early squamous cell carcinoma of the oral tongue: Comparing margins obtained from the glossectomy specimen to margins from the tumor bed. Oral Oncology, 2013, 49, 1077-1082.	1.5	64
45	Transition to a virtual multidisciplinary tumor board during the COVID â€19 pandemic: University of Pittsburgh experience. Head and Neck, 2020, 42, 1310-1316.	2.0	64
46	Thyroid nodules with <i>KRAS</i> mutations are different from nodules with <i>NRAS</i> and <i>HRAS</i> mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathology, 2014, 122, 873-882.	2.4	63
47	Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma in an Adult Population Without Radiation Exposure. American Journal of Surgical Pathology, 2017, 41, 446-457.	3.7	61
48	JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. Neoplasia, 2015, 17, 256-264.	5.3	59
49	The spatial targeting and nuclear matrix binding domains of SRm160. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3269-3274.	7.1	58
50	The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. Journal of Cellular Physiology, 2015, 230, 2683-2694.	4.1	58
51	Clinicopathologic and Immunophenotypic Characterization of 25 Cases of Acinic Cell Carcinoma with High-Grade Transformation. Head and Neck Pathology, 2016, 10, 152-160.	2.6	58
52	<i>THADA</i> fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2307-2312.	7.1	58
53	Re-Evaluating Historic Cohort of Salivary Acinic Cell Carcinoma with New Diagnostic Tools. Head and Neck Pathology, 2012, 6, 166-170.	2.6	56
54	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer, 2013, 13, 602.	2.6	56

#	Article	IF	CITATIONS
55	<scp>HMGA</scp> 2 is a specific immunohistochemical marker for pleomorphic adenoma and carcinoma exâ€pleomorphic adenoma. Histopathology, 2017, 71, 511-521.	2.9	56
56	KRAS mutant allele-specific imbalance in lung adenocarcinoma. Modern Pathology, 2011, 24, 1571-1577.	5.5	53
57	Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry. Head and Neck Pathology, 2017, 11, 288-294.	2.6	53
58	Mutant alleleâ€specific imbalance modulates prognostic impact of <i>KRAS</i> mutations in colorectal adenocarcinoma and is associated with worse overall survival. International Journal of Cancer, 2012, 131, 1810-1817.	5.1	52
59	The HTN3-MSANTD3 Fusion Gene Defines a Subset of Acinic Cell Carcinoma of the Salivary Gland. American Journal of Surgical Pathology, 2019, 43, 489-496.	3.7	52
60	Prospective testing of mucoepidermoid carcinoma for the <i>MAML2</i> translocation: Clinical Implications. Laryngoscope, 2012, 122, 1690-1694.	2.0	51
61	Canalicular Adenoma: A Clinicopathologic and Immunohistochemical Analysis of 67 Cases with a Review of the Literature. Head and Neck Pathology, 2015, 9, 181-195.	2.6	50
62	The prognostic and predictive value of <i>KRAS</i> oncogene substitutions in lung adenocarcinoma. Cancer, 2013, 119, 2268-2274.	4.1	49
63	Measuring Depth of Invasion in Early Squamous Cell Carcinoma of the Oral Tongue: Positive Deep Margin, Extratumoral Perineural Invasion, and Other Challenges. Head and Neck Pathology, 2019, 13, 154-161.	2.6	49
64	Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. Clinical Cancer Research, 2014, 20, 3289-3298.	7.0	48
65	Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Annals of Oncology, 2016, 27, 1594-1600.	1.2	48
66	Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of dicer expression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 629-635.	2.8	47
67	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i> -altered head and neck cancer. Journal of Experimental Medicine, 2019, 216, 419-427.	8.5	46
68	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight, 2017, 2, e90449.	5.0	45
69	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2015, 1, 238.	7.1	44
70	Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma. Histopathology, 2014, 65, 854-860.	2.9	43
71	Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chemical Biology, 2013, 8, 345-352.	3.4	41
72	Characterization of thyroid cancer driven by known and novel ALK fusions. Endocrine-Related Cancer, 2019, 26, 803-814.	3.1	38

#	Article	IF	CITATIONS
73	Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme. Journal of Cell Science, 2004, 117, 5847-5854.	2.0	37
74	TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation. Scientific Reports, 2015, 5, 16657.	3.3	37
75	The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget, 2016, 7, 27185-27198.	1.8	37
76	Oral Squamous Cell Carcinoma with Mandibular Bone Invasion: Intraoperative Evaluation of Bone Margins by Routine Frozen Section. Head and Neck Pathology, 2011, 5, 216-220.	2.6	36
77	Incidence of human papillomavirus in oropharyngeal squamous cell carcinomas: now and 50 years ago. Human Pathology, 2012, 43, 17-22.	2.0	36
78	MAML2 Status in Mucoepidermoid Carcinoma Can No Longer Be Considered a Prognostic Marker. American Journal of Surgical Pathology, 2016, 40, 1151-1153.	3.7	35
79	Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomarkers, 2011, 9, 325-339.	1.7	34
80	Evaluation of NR4A3 immunohistochemistry (IHC) and fluorescence in situ hybridization and comparison with DOG1 IHC for FNA diagnosis of acinic cell carcinoma. Cancer Cytopathology, 2021, 129, 104-113.	2.4	34
81	Thyroid Paragangliomas Are Locally Aggressive. Thyroid, 2012, 22, 88-93.	4.5	33
82	Ameloblastoma and Dentigerous Cyst Associated with Impacted Mandibular Third Molar Tooth. Radiographics, 2010, 30, 1415-1420.	3.3	32
83	Mammary Analogue Secretory Carcinoma Mimicking Salivary Adenoma. Head and Neck Pathology, 2013, 7, 316-319.	2.6	32
84	KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. Modern Pathology, 2014, 27, 262-270.	5.5	32
85	In vitro FRAP reveals the ATP-dependent nuclear mobilization of the exon junction complex protein SRm160. Journal of Cell Biology, 2004, 164, 843-850.	5.2	31
86	Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer. Clinical Cancer Research, 2012, 18, 2850-2860.	7.0	30
87	Intraoperative Margin Assessment in Early Oral Squamous Cell Carcinoma. Surgical Pathology Clinics, 2017, 10, 1-14.	1.7	30
88	Reappraising hyalinizing clear cell carcinoma: A populationâ€based study with molecular confirmation. Head and Neck, 2017, 39, 503-511.	2.0	29
89	EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Human Pathology, 2010, 41, 1053-1060.	2.0	24
90	Phosphaturic Mesenchymal Tumor Involving the Head and Neck: A Report of Five Cases with FGFR1 Fluorescence In Situ Hybridization Analysis. Head and Neck Pathology, 2016, 10, 279-285.	2.6	24

#	Article	IF	CITATIONS
91	Early squamous cell carcinoma of the oral tongue with histologically benign lymph nodes: A model predicting local control and vetting of the eighth edition of the American Joint Committee on Cancer pathologic T stage. Cancer, 2019, 125, 3198-3207.	4.1	24
92	Intraoperative Margin Assessment in Head and Neck Cancer: A Case of Misuse and Abuse?. Head and Neck Pathology, 2020, 14, 291-302.	2.6	24
93	Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein–Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. Head and Neck Pathology, 2017, 11, 203-211.	2.6	23
94	Clear Cell Carcinoma of Salivary Glands Is Frequently p16 Positive. American Journal of Surgical Pathology, 2018, 42, 367-371.	3.7	23
95	Molecular alterations in Hürthle cell nodules and preoperative cancer risk. Endocrine-Related Cancer, 2021, 28, 301-309.	3.1	23
96	Improving margin revision: Characterization of tumor bed margins in early oral tongue cancer. Oral Oncology, 2017, 75, 184-188.	1.5	21
97	Pathology Archive. American Journal of Clinical Pathology, 2011, 135, 753-759.	0.7	20
98	Mucoacinar Carcinoma. American Journal of Surgical Pathology, 2021, 45, 1028-1037.	3.7	20
99	Salivary type tumors seen in consultation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 457-466.	2.8	19
100	Solid Lymph Nodes as an Imaging Biomarker for Risk Stratification in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma. American Journal of Neuroradiology, 2017, 38, 1405-1410.	2.4	18
101	SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications. Head and Neck Pathology, 2021, 15, 1185-1191.	2.6	17
102	Clinicopathologic Characteristics of Thyroid Nodules Positive for the <i>THADA-IGF2BP3</i> Fusion on Preoperative Molecular Analysis. Thyroid, 2021, 31, 1212-1218.	4.5	16
103	The role of adjuvant (chemo-)radiotherapy in oral cancers in the contemporary era. Oral Oncology, 2020, 102, 104563.	1.5	14
104	Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and Poorer Survival. Journal of Thoracic Oncology, 2011, 6, 1407-1412.	1.1	12
105	Does a specimenâ€based margin analysis of early tongue cancer better predict local control?. Laryngoscope, 2016, 126, 2426-2427.	2.0	12
106	Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. BMC Cancer, 2018, 18, 1107.	2.6	12
107	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. Scientific Reports, 2020, 10, 8031.	3.3	12
108	Solid Cell Nests, Papillary Thyroid Microcarcinoma, and HBME1. American Journal of Clinical Pathology, 2010, 134, 169-170.	0.7	10

#	Article	IF	CITATIONS
109	Squamous cell carcinoma metastatic to neck from an unknown primary: The potential impact of modern pathologic evaluation on perceived incidence of human papillomavirus–positive oropharyngeal carcinoma prior to 1970. Laryngoscope, 2012, 122, 793-796.	2.0	10
110	Human Papillomavirus-Associated Adenocarcinoma of the Base of Tongue: Potentially Actionable Genetic Changes. Head and Neck Pathology, 2014, 8, 151-156.	2.6	10
111	Genomic analysis of recurrences and highâ€grade forms of polymorphous adenocarcinoma. Histopathology, 2019, 75, 193-201.	2.9	10
112	Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fineâ€needle aspirates diagnosed as follicular neoplasm of Hürthle cell (oncocytic) type. Cancer Cytopathology, 2021, 129, 788-797.	2.4	9
113	Management of the "Violated Neck―in the era of chemoradiation. Laryngoscope, 2011, 121, 2349-2358.	2.0	8
114	RB1, p16, and Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma. Head and Neck Pathology, 2021, 15, 1109-1118.	2.6	8
115	Hamartoma of the Oral Cavity with Ectopic Meningothelial Elements in Infants: A Rare Entity with Report of Two Cases. Head and Neck Pathology, 2020, 14, 268-271.	2.6	7
116	Margin assessment in oral squamous cell carcinoma. Cancer, 2014, 120, 452-453.	4.1	6
117	Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract. Head and Neck Pathology, 2021, 15, 769-779.	2.6	6
118	Colorectal carcinomas, KRAS p.G13D mutant allele–specific imbalance, and anti–epidermal growth factor receptor therapy. Cancer, 2013, 119, 4366-4366.	4.1	3
119	Alternate diagnostic test interpretation in a retrospective convenience cohort and clinical application of <scp>MPTX</scp> . Diagnostic Cytopathology, 2021, 49, 347-348.	1.0	3
120	Tribute: E. Leon Barnes, M.D. Head and Neck Pathology, 2012, 6, 54-57.	2.6	2
121	Metastasis of Breast Carcinoma to the Maxillary Sinus. Breast Journal, 2014, 20, 318-319.	1.0	2
122	Standardized Margin Assessment Is Needed Before Implementing Negative Margin as a Quality Measure. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 541.	2.2	2
123	Pathology Quiz Case 3. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 533.	2.2	1
124	Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy. Endocrine-Related Cancer, 2015, 22, L19-L22.	3.1	1
125	Patients with revised surgical resection margins are best studied as a distinct group. Cancer, 2018, 124, 4262-4263.	4.1	1
126	Malignant Neoplasms of the Salivary Glands. , 2019, , 284-362.e5.		1

Malignant Neoplasms of the Salivary Glands. , 2019, , 284-362.e5. 126

#	Article	IF	CITATIONS
127	On challenges of disproving inferiority of tumor bed margins. Oral Diseases, 2019, 25, 2040-2041.	3.0	1
128	First needle marrow biopsy to diagnose a systemic illness. Blood, 2012, 120, 4910-4910.	1.4	0
129	MicroRNAs in Endocrine Diseases. Molecular Pathology Library, 2010, , 21-24.	0.1	Ο